Knight Therapeutics Inc. of Quebec has inked an exclusive contract with Middle Eastern company EMPA Healthcare LLC to market Neuragen, a natural topical pain reliever for sufferers of peripheral neuropathy, Knight announced recently from Montreal.
EMPA, based in the United Arab Emirates (UAE) and Kuwait — and operating with four divisions consisting of health care, distribution, business solutions and retail — will handle distribution and sales of Neuragen throughout the UAE, Kuwait and Gulf Cooperation Council (GCC) nations while Knight shores up product manufacturing and supply. If GCC countries meet sales goals, Knight may broaden distribution to additional states.
"I am delighted that EMPA Healthcare will be representing Knight in the promotion and distribution of Neuragen in the United Arab Emirates and Kuwait,” Michel Loustric, president of Knight Therapeutics (Barbados) Inc., said. “EMPA's distinguished business approach which includes building strong relationships with customers and health care stakeholders to provide outstanding health care services is in keeping with the core values of Knight. Together, Knight and EMPA will be able to offer relief to those suffering from peripheral nerve pain."
Unlike orally ingested pharmaceuticals, Neuragen acts on nerve pain by absorption into the skin. Scientists believe its effectiveness derives from reducing stimulation of damaged nerves without as many side effects as documented in oral medications.
"We are pleased to be working with Knight on launching Neuragen in the UAE and Kuwait," Moutassem Sharaf, EMPA Healthcare LLC managing director, said. "We appreciate the trust that the Knight team have placed in us to make this important product available to patients experiencing peripheral nerve pain in the Middle East."